Immunocore
Update in progressIMCR (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Immunocore Holdings plc and its subsidiaries develop immunomodulating medicines for cancer, infectious diseases, and autoimmune conditions across the United States, Europe, and globally. It offers KIMMTRAK for unresectable or metastatic uveal melanoma and has multiple programs, including tebentafusp (Phase 3 for advanced cutaneous melanoma and adjuvant uveal melanoma), brenetafusp (Phase 3 for first-line advanced cutaneous melanoma; Phase 1/2 for other tumors), IMC-R117C, IMC-P115C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI. Founded 1999, HQ in Abingdon, UK.
Company score
- Sentiment
- 0.31
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.32
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!